Menu Search
Equities

Willow Biosciences Inc

WLLW:TOR

Willow Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.09
  • Today's Change-0.005 / -5.26%
  • Shares traded98.10k
  • 1 Year change+20.00%
  • Beta1.1653
Data delayed at least 15 minutes, as of Nov 08 2024 20:43 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Willow Biosciences Inc grew revenues 42.75% from 821.00k to 1.17m while net income improved from a loss of 14.81m to a smaller loss of 13.03m.
Gross margin--
Net profit margin-472.83%
Operating margin-458.42%
Return on assets-117.73%
Return on equity-212.20%
Return on investment-164.04%
More ▼

Cash flow in CADView more

In 2023, cash reserves at Willow Biosciences Inc fell by 7.86m. However, Cash Flow from Investing totalled 3.47m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 10.92m for operations while cash used for financing totalled 318.00k.
Cash flow per share-0.0563
Price/Cash flow per share--
Book value per share-0.0004
Tangible book value per share-0.0004
More ▼

Balance sheet in CADView more

Willow Biosciences Inc has a Debt to Total Capital ratio of 103.01%, a higher figure than the previous year's 14.59%.
Current ratio0.7005
Quick ratio0.6479
Total debt/total equity--
Total debt/total capital1.03
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.